OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII

By Jonathan Smith at Labiotech.eu Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and

Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB) Clinical trial preparations of OMN6 under way Jerusalem, Israel — Omnix Medical, a Jerusalem-based biopharmaceutical

New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we